Johnson & Johnson has entered into a $1.25 billion agreement to acquire NM26, a bispecific antibody for atopic dermatitis (AD) from Numab Therapeutics. NM26 targets IL-4 receptors and IL-31, offering potential first-in-class therapy benefits for AD patients. The deal underscores J&J's commitment to developing innovative treatments for inflammatory diseases.
Johnson & Johnson will acquire Yellow Jersey Therapeutics for $1.25 billion, gaining rights to NM26, a Phase 2-ready bispecific antibody for atopic dermatitis.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.